Your browser doesn't support javascript.
loading
Epigenetic dysregulation in meningiomas.
Wedemeyer, Michelle A; Muskens, Ivo; Strickland, Ben A; Aurelio, Oscar; Martirosian, Vahan; Wiemels, Joseph L; Weisenberger, Daniel J; Wang, Kai; Mukerjee, Debraj; Rhie, Suhn K; Zada, Gabriel.
Afiliação
  • Wedemeyer MA; Department of Neurosurgery, University of California San Francisco, Benioff Children's Hospitals, San Francisco, California, USA.
  • Muskens I; Children's Cancer Research Laboratory, Center of Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Strickland BA; Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Aurelio O; Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Martirosian V; Brain Tumor Center, University of Southern California, Los Angeles, California, USA.
  • Wiemels JL; Children's Cancer Research Laboratory, Center of Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Weisenberger DJ; Department of Biochemistry and Molecular Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Wang K; Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia Research Institute, Philadelphia, Pennsylvania, USA.
  • Mukerjee D; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Rhie SK; Department of Biochemistry and Molecular Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Zada G; Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Neurooncol Adv ; 4(1): vdac084, 2022.
Article em En | MEDLINE | ID: mdl-35769412
ABSTRACT

Background:

Meningiomas are the most common primary brain tumor. Though typically benign with a low mutational burden, tumors with benign histology may behave aggressively and there are no proven chemotherapies. Although DNA methylation patterns distinguish subgroups of meningiomas and have higher predictive value for tumor behavior than histologic classification, little is known about differences in DNA methylation between meningiomas and surrounding normal dura tissue.

Methods:

Whole-exome sequencing and methylation array profiling were performed on 12 dura/meningioma pairs (11 WHO grade I and 1 WHO grade II). Single-nucleotide polymorphism (SNP) genotyping and methylation array profiling were performed on an additional 19 meningiomas (9 WHO grade I, 5 WHO grade II, 4 WHO grade III).

Results:

Using multimodal studies of meningioma/dura pairs, we identified 4 distinct DNA methylation patterns. Diffuse DNA hypomethylation of malignant meningiomas readily facilitated their identification from lower-grade tumors by unsupervised clustering. All clusters and 12/12 meningioma-dura pairs exhibited hypomethylation of the gene promoters of a module associated with the craniofacial patterning transcription factor FOXC1 and its upstream lncRNA FOXCUT. Furthermore, we identified an epigenetic continuum of increasing hypermethylation of polycomb repressive complex target promoters with increasing histopathologic grade.

Conclusion:

These findings support future investigations of the role of epigenetic dysregulation of FOXC1 and cranial patterning genes in meningioma formation as well as studies of the utility of polycomb inhibitors for the treatment of malignant meningiomas.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Neurooncol Adv Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Neurooncol Adv Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos